Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer

Joshua E. Meyer • 20 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Pancreatic Cancer
Alliance A021501

Joshua E. Meyer, MD, Fox Chase Cancer Center, Philadelphia, PA, explores some highlights from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the results of the Alliance A021501 study in pancreatic cancer, where the hypofractionated radiotherapy (RT) arm of the study was closed early. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Joshua E. Meyer

1:39
Novel approaches in the treatment of GI malignancies
Joshua E. Meyer • 20 Jan 2021
2:25
Adjuvant therapy for esophageal cancer
Joshua E. Meyer • 20 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals